AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Subcontract given to develop anthrax vaccines using nanotechnology.
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BPA) announced that it has been awarded a subcontract valued at $658,207 for the development of anthrax vaccines for delivery via alternative routes of administration.
The subcontract was awarded to BioSante by DynPort Vaccine Company, LLC, (DVC) in support of the U.S. Department of Defense Joint Vaccine Acquisition Program (JVAP).
This subcontract leverages the technology and expertise of BioSante to develop vaccines using alternative routes of administration, including nasal, oral, and needle-free transcutaneous routes. Under the subcontract, BioSante will provide BioVant, its proprietary nanotechnology-based vaccine adjuvant and delivery system, and DVC will provide recombinant antigens to be used in potential vaccines against anthrax. The objective is to assess the immunogenic potential of BioVant when used in anthrax vaccines versus the immunogenic response of anthrax vaccines that use Alhydrogel as the vaccine adjuvant.
BioSante is responsible for developing formulations of BioVant with the anthrax vaccine antigens and will conduct immunization studies in animals to determine the immunogenicity of the ...
- BioSante Pharmaceuticals Announces DynPort Subcontract to Develop Anthrax...
- Press release article from: Business Wire January 7, 2004 700+ words
...development of anthrax vaccines for delivery...was awarded to BioSante by DynPort Vaccine...when used in anthrax vaccines versus the immunogenic response of anthrax vaccines that use Alhydrogel...vaccine adjuvant. BioSante is responsible...
- BioSante Pharmaceuticals announces DynPort subcontract to develop anthrax...
- News wire article from: Asia Africa Intelligence Wire January 7, 2004 700+ words
...Pharmaceuticals Inc (BioSante) has been awarded...the development of anthrax vaccines for delivery via alternative...subcontract was awarded to BioSante by DynPort Vaccine...immunogenic response of anthrax vaccines that use Alhydrogel as the vaccine adjuvant. BioSante is ...
- BioSante Pharmaceuticals Presents New Anthrax Vaccine Data at World Vaccine...
- Press release article from: Business Wire April 19, 2005 700+ words
...chief executive officer of BioSante. "We are pleased with these...About BioVant Formulated using BioSante's proprietary CaP nanotechnology...intranasally administered anthrax vaccines. While injectable aluminum...reaction after administration. BioSante is developing BioVant under...
- BioSante Pharmaceuticals Presents CaP Nanotechnology Review at International...
- Press release article from: Business Wire May 18, 2005 700+ words
...clinical development for BioSante, will present a review of...About BioVant Formulated using BioSante's proprietary CaP nanotechnology...intranasally administered anthrax vaccines, among other uses. While...reaction after administration. BioSante is developing BioVant under...
- BioSante Pharmaceuticals Presents Anthrax Vaccine Update At World Vaccine...
- Press release article from: Business Wire October 18, 2004 700+ words
...chief executive officer of BioSante. "A vaccine that doesn...versatility and safety profile." BioSante's CAP nanotechnology-based...is being tested for use in anthrax vaccines that can be administered by...Under the subcontract, BioSante is formulating BioVant with...
- BioSante Pharmaceuticals presents CaP nanotechnology review at International...
- News wire article from: Asia Africa Intelligence Wire May 18, 2005 700+ words
...am CEST (3:30 am ET). BioSante will provide a review of progress...applications. Formulated using BioSante's proprietary CaP nanotechnology...intranasally administered anthrax vaccines, among other uses. While...reaction after administration. BioSante is developing BioVant under...
- BioSante gets DynPort anthrax subcontract.(Brief Article)
- Newspaper article from: Pharma Marketletter January 19, 2004 700+ words
BioSante Pharmaceuticals has been...DynPort Vaccine Co to develop anthrax vaccines for delivery via alternative...terms of the subcontract, BioSante will provide its proprietary...vaccines against anthrax. BioSante holds responsibility for...
- BioSante Pharmaceuticals Announces Management Changes.
- Press release article from: Business Wire December 2, 2005 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that BioSante has engaged Michael C. Snabes, M.D...as an independent consultant to work with BioSante's current product development team in...
- BioSante Licenses Portfolio of Innovative Hormone Replacement Therapies to...
- Press release article from: PR Newswire September 5, 2000 700+ words
...MONTREAL, Sept. 5 /PRNewswire/ - BioSante Pharmaceuticals, Inc. (OTCBB:BTPH...agreement whereby Paladin will sub-license BioSante's portfolio of female hormone replacement...in Canada. "This agreement provides BioSante a strong partner with proven expertise...
- BioSante Pharmaceuticals Reports LibiGel[R] Status and Financial Results for...
- Press release article from: Business Wire March 16, 2009 700+ words
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ...year ended December 31, 2008. "BioSante had an excellent year in 2008. Our...trials," said Stephen M. Simes, BioSante's president and chief executive...
Source: HighBeam Research, Subcontract given to develop anthrax vaccines using nanotechnology.